Replies to post #200885 on Avid Bioservices Inc (CDMO)

[InternetForumUser]

That statement was not made on 12/14...

[biopharm]

atonewithPPHM, here is the article: ... may be my fault for squeezing too many links of info in some posts but I did go thru the chain of links to the source on June 3, 2013

June 3, 2013

"Immunotherapies have shown significant promise in treating solid tumors and it is encouraging to see these latest results from bavituximab in second-line NSCLC. Bavituximab is a unique targeted immunotherapy with a novel mechanism of action that potentially synergizes well with other compounds currently being developed for oncology," said Martin J. Edelman, M.D., Professor of Medicine at the University of Maryland Greenebaum Cancer Center. "I look forward to being involved in the upcoming Phase III trial and to seeing the potential of bavituximab in other indications and combinations."

http://www.pharmacychoice.com/News/article.cfm?Article_ID=1061209